Role of serotonin in obsessive-compulsive disorder

被引:76
作者
Baumgarten, HG [1 ]
Grozdanovic, Z [1 ]
机构
[1] Free Univ Berlin, Clin Benjamin Franklin, Inst Anat, D-14195 Berlin, Germany
关键词
D O I
10.1192/S0007125000297857
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Serotonin may play a role in the pathophysiology of obsessive-compulsive disorder (OCD) because of the anti-obsession ai effect of selective serotonin reuptake inhibitors (SSRIs). Method The literature is reviewed on knowledge of the role of serotonergic neurons in brain function, studies on monoamine metabolites in cerebrospinal fluid (CSF), various stress neuropeptides, neuroendocrine and behavioural challenge after administration of direct and indirect serotomimetic compounds, and neuroanatomical data on brain circuits organising behaviour. Results in most of the OCD cases analysed, CSF 5-hydroxyindoleacetic acid and homovanillic acid concentrations do not significantly differ from age-corrected controls. However, a relationship appears to exist between pre-treatment levels of these metabolites and clinical response to drugs acting on the serotonin transporter. Abnormalities in CSF arginine vasopressin, corticotropin-releasing hormone, oxytocin and somatostatin levels have been reported in OCD. long-term treatment with high-doses of clomipramine, fluvoxamine, and fluoxetine tend to correct these neuropeptide abnormalities. Conclusions We hypothesise that continuous treatment with SSRIs alters serotonin turnover and neuropeptide expression patterns in OCD-entertaining functional forebrain/midbrain circuits.
引用
收藏
页码:13 / 20
页数:8
相关论文
共 73 条
  • [1] Aghajanian GK, 1997, HANDB EXP PHARM, V129, P499
  • [2] INTERACTING NEUROTRANSMITTER SYSTEMS - A NONEXPERIMENTAL APPROACH TO THE 5HIAA-HVA CORRELATION IN HUMAN CSF
    AGREN, H
    MEFFORD, IN
    RUDORFER, MV
    LINNOILA, M
    POTTER, WZ
    [J]. JOURNAL OF PSYCHIATRIC RESEARCH, 1986, 20 (03) : 175 - 193
  • [3] ALTEMUS M, 1994, ARCH GEN PSYCHIAT, V51, P794
  • [4] ALTEMUS M, 1993, AM J PSYCHIAT, V150, P460
  • [5] ALTEMUS M, 1992, ARCH GEN PSYCHIAT, V49, P9
  • [6] ASBERG M, 1977, CLIN PHARMACOL THER, V21, P201
  • [7] BARR LC, 1994, ARCH GEN PSYCHIAT, V51, P309
  • [8] BASTANI B, 1990, ARCH GEN PSYCHIAT, V47, P833
  • [9] Psychopharmacology of central serotonergic systems
    Baumgarten, HG
    Grozdanovic, Z
    [J]. PHARMACOPSYCHIATRY, 1995, 28 : 73 - 79
  • [10] Baumgarten HG, 1997, HANDB EXP PHARM, V129, P41